Quality of life should be the primary outcome for disease-modifying therapy trials in MS-Yes.
Multiple sclerosis (Houndmills, Basingstoke, England)（2023）
关键词
ms—yes,therapy trials,primary outcome,disease-modifying
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要